BRANY Launches "Smart-Start-60" to Expedite Clinical Trials
Biomedical Research Alliance of New York (BRANY), has introduced “Smart-Start-60,” a program that initiates clinical trials within 60 days at any of BRANY’s certified investigator sites. Once a site has been selected, BRANY immediately begins budget development, contract negotiations, completion of regulatory documents (including ICF modifications), and IRB submission and review.
On the occasion of the launch of Smart-Start-60, BRANY is offering new and returning clients an introductory rate. Please contact Carmela Houston-Henry for more information at choustonhen@brany.com.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
